| Literature DB >> 32896985 |
Long Bai1,2,3, Lu Sun1,2,3, Wei Chen1,2,3, Kai-Yu Liu1,2,3, Chun-Feng Zhang1,2,3, Fei Wang2,4, Gui-Huan Zhang1,2,3, Ye Huang1,2,3, Jing-Xuan Li1,2,3, Ying Gao1,2,3, Xin Sun2,3,5, Wei Liu2, Guo-Qing Du2,3,4, Ren-Ke Li6,7, Ming-Li Huang2,3,5, Hai Tian1,2,3.
Abstract
Stem cell transplantation is nearly available for clinical application in the treatment of ischaemic heart disease (IHD), where it may be joined traditional methods (intervention and surgery). The angiogenic ability of seed cells is essential for this applicability. The aim of this study was to reveal the presence of CD34+ angiogenic stem cells in human decidua at the first trimester and to use their strong angiogenic capacity in the treatment of IHD. In vitro, human decidual CD34+ (dCD34+ ) cells from the first trimester have strong proliferation and clonality abilities. After ruling out the possibility that they were vascular endothelial cells and mesenchymal stem cells (MSCs), dCD34+ cells were found to be able to form tube structures after differentiation. Their angiogenic capacity was obviously superior to that of bone marrow mesenchymal stem cells (BMSCs). At the same time, these cells had immunogenicity similar to that of BMSCs. Following induction of myocardial infarction (MI) in adult rats, infarct size decreased and cardiac function was significantly enhanced after dCD34+ cell transplantation. The survival rate of cells increased, and more neovasculature was found following dCD34+ cell transplantation. Therefore, this study confirms the existence of CD34+ stem cells with strong angiogenic ability in human decidua from the first trimester, which can provide a new option for cell-based therapies for ischaemic diseases, especially IHD.Entities:
Keywords: angiogenic stem cells; bone marrow mesenchymal stem cells; cell transplantation; decidual CD34+ cells; ischaemic heart disease
Mesh:
Substances:
Year: 2020 PMID: 32896985 PMCID: PMC7578869 DOI: 10.1111/jcmm.15800
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Primers used for real‐time PCR
| Name | Sequence |
|---|---|
| CD31‐F | 5′‐TGAGGTCAAAGGATCAGACGAC‐3′ |
| CD31‐R | 5′‐TGGTGGCAAGGGACTAAGGA‐3′ |
| VE‐cadherin‐F | 5′‐ATGAGATCGTGGTGGAAGCG‐3′ |
| VE‐cadherin‐R | 5′‐ATGTGTACTTGGTCTGGGTGA‐3′ |
| VEGFR‐2‐F | 5′‐TCTGCCTACCTCACCTGTTTC‐3′ |
| VEGFR‐2‐R | 5′‐TCTGCCTACCTCACCTGTTTC‐3′ |
| GAPDH‐F | 5′‐GTGGGATGCAACAGCCTTAGA‐3′ |
| GAPDH‐R | 5′‐CGCTCCTGGAAGATGGTGAT‐3′ |
FIGURE 1Discovery of CD34+ precursors in human decidua. A, Immunohistochemical analysis of decidual tissues and staining with CD34‐specific mAbs. The yellow arrows indicate CD34+ vessels. The green arrows indicate CD34+‐positive cells. B, Flow cytometry showed that the expression of CD34+/c‐kit‐ was found in 5.68 ± 0.66% of the cells in decidua. C, After bead sorting, 79.58 ± 3.77% of cells were CD34+. D, Most of the dCD34+ cells were c‐kit‐. E,F, dCD34+ cells hardly expressed mesenchymal cell‐specific markers CD90 and CD105. G, Individual dCD34+ cells had round shapes, and the boundaries were clear. H, Morphology of a representative colony derived from dCD34+ cells over 15 d. I, Clonal quantities increased with the cell inoculation densities (ANOVA; **P < 0.01; ***P < 0.001; and n = 4/group). Scale bars in (A,G) represent 100 μm; in H, it represents 50 μm
FIGURE 2Validation of non‐vascular endothelial cells. A, CD31, VE‐cadherin and VEGFR‐2 were strongly expressed in UVECs, CD31 and VE‐cadherin were weakly expressed in dUCs, and all were unexpressed in dCD34+ cells. B‐D, dCD34+ cells did not express the above three characteristic endothelial cell markers, as assessed by FACS (n = 4/group)
FIGURE 3Analysis of angiogenesis and paracrine effect in dCD34+ cells. A, dCD34+ cells began to differentiate into adherent cells (green arrow) in 5 d, and increasing numbers of adherent cells appeared until 15 d. B, Induced dCD34+ cells (adherent) and BMSCs could express CD31 and vWF, as shown by immunofluorescence staining. (C,D) Tube formation of dCD34+ cells (adherent) and BMSCs was assessed in Matrigel. dCD34+ cells formed more tubule structures than BMSCs did. (E,F) In vitro release of VEGF, bFGF from dCD34+ cells compared with BMSCs (two‐tailed t test; **P < 0.05; ***P < 0.001; and n = 4/group). Scale bars in (A‐C) represent 100 μm
FIGURE 4Immunological characteristics of dCD34+ cells. A, Flow cytometry showed that dCD34+ cells weakly expressed HLA‐ABC and hardly expressed HLA‐DR; the results were the same in BMSCs. B, Almost the same cytotoxicity was observed in dCD34+ cells and BMSCs. LDH release reagent treatment was used as a positive control of LDH release, which was much higher than the other two groups (ANOVA; ***P < 0.001; and n = 4/group). (C,D) After 5 d of coculture, the lymphocytes of three groups were removed and stained for CD4 and CD8, then measured by flow cytometry (ANOVA; **P < 0.05; ***P < 0.001; and n = 4/group)
FIGURE 5Cell therapy for IHD. A, Masson's trichrome staining of the infarct size 4 wk after cell transplantation in the three groups (blue = collagen; red = myocardium). Scale bars represent 2 mm. B, The infarct size of the dCD34+ group was significantly smaller than that of the medium control and BMSC group 4 wk after MI, and the infarct size of the BMSC group was also significantly smaller than that of the control. C, Representative echocardiography images from the three groups before and 1 and 4 wk after MI (high lines: LVESd; low lines: LVEDd). D, The LVEF and LVFS of the dCD34+ group after MI were significantly higher than those of the control and BMSC groups. The LVESd and LVEDd of the dCD34+ group after MI were significantly smaller than those of the control and BMSC groups. The same results were observed in the BMSC group compared to the control (ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001; and n = 6/group)
FIGURE 6Cell survival and neovascularization. A, Anti‐human mitochondrial staining showed the survival of transplanted cells. B, The number of dCD34+ cells that survived was significantly greater than that in the BMSC group 7 and 28 d after cell transplantation. C, Staining for a‐SMA and CD31 (red arrows) was used to visualize the blood vessel density. (D,E) Arteriole and capillary densities were higher in the dCD34+ group than they were in the other two groups at 28 d after MI. The same results were observed in the BMSC group and in the control (ANOVA; *P < 0.05, ***P < 0.001; and n = 6/group). Scale bars in (A,C) represent 100 μm